Click here to join our Discord:  Real Peptide Talk
Visit our store:  https://NRGBioLabs.com
Visit our blog:   https://peptideresearch.us
Join our Newsletter list:  https://peptideresearch.us/newsletter
Follow us on Facebook

In this episode of The Peptide Research Podcast, we take a closer look at ARA-290, also known as cibinetide, a research peptide designed to activate the body’s natural repair signaling without stimulating red blood cell production.

ARA-290 has drawn attention in the scientific community for its potential role in calming inflammation, supporting nerve health, and influencing tissue recovery. Much of the human research has focused on small fiber neuropathy, particularly in people with sarcoidosis, where studies have explored both symptom improvement and objective nerve fiber measurements. Additional research has examined ARA-290 in diabetic neuropathy, diabetic eye disease, and broader inflammatory and tissue stress models.

We break down how ARA-290 works through what researchers call the innate repair receptor, why it is considered non erythropoietic, and how it differs from erythropoietin itself. We also discuss what the published safety data actually shows, what remains unknown, and why this peptide continues to be studied years after its initial development.

If you are interested in peptides that focus on repair signaling rather than symptom suppression, this episode offers a clear, grounded overview of the science behind ARA-290 and where it fits in the evolving peptide research landscape.